Here's Why You Should Retain NeuroPace Stock in Your Portfolio for NowZacks Investment Research • 09/04/26
NeuroPace Faces an IGE Delay: What the FDA Setback Means for GrowthZacks Investment Research • 08/17/26
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?Zacks Investment Research • 08/17/26
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?Zacks Investment Research • 08/17/26
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View UpZacks Investment Research • 08/12/26
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue GuidanceBusiness Wire • 08/11/26
NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy TranscriptSeeking Alpha • 07/29/26
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized EpilepsyBusiness Wire • 07/28/26
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to TradeZacks Investment Research • 06/15/26
NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/11/26
NPCE Receives FDA Approval for AI-Powered ECoG Assistant for EpilepsyZacks Investment Research • 06/02/26
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) MeetingBusiness Wire • 05/29/26
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy CareBusiness Wire • 05/29/26
NPCE Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook RaisedZacks Investment Research • 05/13/26